17

Sep2015

Private Payer Product Listing Agreement (PLA) Series

Report 3: Experience Negotiating Private Payer PLAs PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this survey, which was conducted ... Read More

09

Sep2015

Private Payer Product Listing Agreement (PLA) Series

Report 2: Negotiation-Naïve & Interested in Negotiating a Private Payer PLA PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product Listing Agreement (PLA) Series, which provides the results of an online survey of a select group of Canadian private payers and manufacturers. The purpose of this ... Read More

03

Sep2015

Private Payer Product Listing Agreement (PLA) Series

Report 1: Negotiation-Naïve & No Interest in Negotiating a Private Payer PLA PDCI Market Access (PDCI) and H3 Consulting (H3) conducted an online survey of a select group of Canadian pharmaceutical manufacturer and private payer stakeholders to provide clarity on the evolving private payer product listing agreement (PLA) landscape. We thank ... Read More

08

Jun2015

PDCI International Trends Series Part 5

PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were public and private payers, and industry stakeholders in both Canada and Europe. The final issue in this series reveals stakeholder’s perspectives on exclusivity agreements in ... Read More

26

May2015

PDCI International Trends Series Part 4

PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada. The current issue presents the perspectives of stakeholders on the biosimilar market.  Recent experience in Norway ... Read More

19

May2015

PDCI International Trends Series Part 3

PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada.  The current issue presents the perspectives of both private and public payers, and industry representatives ... Read More

14

May2015

PDCI International Trends Series Part 2

PDCI Market Access recently launched the International Trends Series, which provides the results of an online survey PDCI conducted between March 19, 2015 and March 25, 2015. Participants were stakeholders in Europe and Canada.  The first issue, “Delisting of Oncology Treatments” was released last week. This current issue reveals the ... Read More

04

May2015

PDCI International Trends Series

In preparation for the recent Pharma Symposium conference held in Toronto on March 31-April 1, PDCI conducted an online survey of a select group of pharmaceutical stakeholders in Canada and Europe.  The purpose of this survey was to gauge whether some of the cost containment mechanisms being implemented in certain ... Read More

09

Feb2015

Interview with pCPA on the Guidelines for Negotiations

PDCI Market Access Inc. interviewed a representative from one of the pan-Canadian Pharmaceutical Alliance (pCPA) lead provinces and has produced an article providing guidance for negotiating with the pCPA. The pCPA has completed approximately 50 negotiations since it was established in 2010, but stakeholders are still looking for greater transparency ... Read More

07

Oct2014

PDCI Pan-Canadian Pharmaceutical Alliance (PCPA) Benchmarking Survey Report – NOW AVAILABLE!

PDCI Market Access has completed its benchmarking survey on the pan-Canadian Pharmaceutical Alliance (PCPA).  We received responses from manufacturers of 7 products that have successfully navigated this important reimbursement process.  The purpose of the survey was to gain a better understanding of the PCPA experience from the company perspective. The survey ... Read More